RE:RE:I'm concerned ."Here's the difference: they had a plan for Rome." Why don't you think developing a pharma-grade avenanthramide pill and approving a Phase I/IIa clinical trial with Health Canada is a plan? It will generate safety/tolerability and preclininary efficacy data. Should they forego human clinical trial data? Is that your plan? Why don't you think scaling up PGX 5X and 10X is a plan? If you don't scale up what do you propose as an alternative plan? No path to scale-up? A number of use cases for PGX have been tested. PGX-YBG has been tested in human cell-lines and found multi-fold more immune stimulative supporting its potential as an immune booster. The PGX-YBG/CoQ10 study at the University of Alberta was found to beat the industry gold standard. Dr. Martin Kolb says if preclinical results are replicated in humans for PGX-YBG/fibrosis it could profoundly change the treatment landscape. Results with McMaster have been sent to a leading scientific journal for peer-review and potential publishing. As opposed to proving up a number of use cases what would your plan be? To further execute CZO has merged with AEZS to build critical mass by adding human resources and capital. It is now optimized to advance its transformational programs. Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”
Would your plan be to not add the necessary human resources and capital to optimize the company to move forwards their transformational products? Would you stay a suboptimal company on the TSX-V without neccessary capital and resources? What would your plan be?